MY130957A - Triazine derivatives and their application as antitelomerase agents - Google Patents

Triazine derivatives and their application as antitelomerase agents

Info

Publication number
MY130957A
MY130957A MYPI20021036A MYPI20021036A MY130957A MY 130957 A MY130957 A MY 130957A MY PI20021036 A MYPI20021036 A MY PI20021036A MY PI20021036 A MYPI20021036 A MY PI20021036A MY 130957 A MY130957 A MY 130957A
Authority
MY
Malaysia
Prior art keywords
agents
antitelomerase
application
triazine derivatives
relates
Prior art date
Application number
MYPI20021036A
Other languages
English (en)
Inventor
Mailliet Patrick
Mergny Jean-Louis
Laoui Abdelazize
Riou Jean-Francois
Doerflinger Gilles
Hamy Francois
Caulfield Thomas
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MY130957A publication Critical patent/MY130957A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20021036A 2001-03-23 2002-03-22 Triazine derivatives and their application as antitelomerase agents MY130957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR0110370 2001-08-02

Publications (1)

Publication Number Publication Date
MY130957A true MY130957A (en) 2007-07-31

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021036A MY130957A (en) 2001-03-23 2002-03-22 Triazine derivatives and their application as antitelomerase agents

Country Status (11)

Country Link
EP (1) EP1373252A1 (https=)
JP (1) JP2004524349A (https=)
AR (1) AR034297A1 (https=)
AU (1) AU2002251140B2 (https=)
CA (1) CA2442012A1 (https=)
CO (1) CO5380035A1 (https=)
IL (2) IL158056A0 (https=)
MX (1) MXPA03008269A (https=)
MY (1) MY130957A (https=)
PE (1) PE20020959A1 (https=)
WO (1) WO2002076975A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003253735A1 (en) * 2002-06-25 2004-01-06 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CN101180061A (zh) * 2005-05-19 2008-05-14 普罗米蒂克生物科学公司 化合物、含有此类化合物的组合物、和治疗转移性黑素瘤和其它癌症的方法
EP2441757A1 (en) * 2006-07-31 2012-04-18 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
US8415340B2 (en) * 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
US20210024455A1 (en) * 2018-03-20 2021-01-28 Hiroshima University Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
SK7402002A3 (en) * 1999-11-29 2002-11-06 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체

Also Published As

Publication number Publication date
AR034297A1 (es) 2004-02-18
WO2002076975A1 (fr) 2002-10-03
JP2004524349A (ja) 2004-08-12
IL158056A0 (en) 2004-03-28
AU2002251140B2 (en) 2007-03-15
PE20020959A1 (es) 2002-12-17
MXPA03008269A (es) 2004-10-15
EP1373252A1 (fr) 2004-01-02
CA2442012A1 (fr) 2002-10-03
IL158056A (en) 2010-02-17
CO5380035A1 (es) 2004-03-31

Similar Documents

Publication Publication Date Title
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DE60112974D1 (en) Carbolinderivate
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
EP1432714A4 (en) CHEMICAL COMPOUNDS
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY128924A (en) Novel compounds
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MXPA04003796A (es) Tioacetamidas sustituidas.
MXPA03007142A (es) Derivados de carbolina.
HUP0500424A2 (en) Combination therapy for the treatment of cancer
MXPA03010761A (es) Combinaciones farmaceuticas.
YU8804A (sh) Jedno-dozni azitromicin
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
PT1463735E (pt) Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas
GB0215526D0 (en) Anticancer compounds
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
AU2001280754A1 (en) Enhancement of photodynamic therapy by anti-angiogenic treatment
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
EP1436279A4 (en) CHEMICAL COMPOUNDS